Results 211 to 220 of about 221,983 (338)

Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The clinical effectiveness of tezacaftor‐ivacaftor in children with cystic fibrosis (cwCF) varies; some patients respond while others do not or have adverse effects. The pharmacokinetics (PK) of tezacaftor‐ivacaftor are inadequately published, especially in children.
Steffie E. M. Vonk   +7 more
wiley   +1 more source

Determination of Pesticide Residues in Fresh Fruits in the Serbian Market by LC-MS/MS. [PDF]

open access: yesFoods
Kecojević I   +10 more
europepmc   +1 more source

Prescription drug use in breastfeeding mothers and infant exposure: A register‐based cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Breast milk is the optimal infant nutrition; however, many infants may be exposed to prescription drugs if used by their mothers during breastfeeding. The aim of this study was to evaluate the prevalence and patterns of prescription drug use among breastfeeding mothers and to assess the availability of relative infant dose information for
Ditte Resendal Gotfredsen   +5 more
wiley   +1 more source

Resistance to Triazoles in Populations of <i>Mycosphaerella fijiensis</i> and <i>M. musicola</i> from the Sigatoka Disease Complex from Commercial Banana Plantations in Minas Gerais and São Paulo, Brazil. [PDF]

open access: yesMicroorganisms
da Silva AG   +11 more
europepmc   +1 more source

Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Due to extensive pathophysiological changes in critically ill patients, standard dosing of antibiotics may lead to inadequate drug exposure. This is concerning, as insufficient plasma drug concentrations may lead to treatment failure, whereas excessive drug exposure may increase the risk of toxic adverse events.
Sarah Dräger   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy